Company: LNAI
Filing Date: 2025-10-15
Form Type: DEF 14A
Source: 0001731122-25-001378
Chunk: 21

Company: Lunai Bioworks Inc.
Filing Date: 2025-10-15
Form: DEF 14A
Chunk 21
---
 current and former executive officers, as determined by our Compensation
Committee.

Insider Trading Policy and Anti-Hedging and Anti-Pledging Policies

We have adopted an Insider Trading Policy that are reasonably designed to promote compliance with insider trading laws, rules and regulations and any applicable listing standards. The policy prohibits directors, officers and employees of the Company from purchasing or selling any Company security while in possession of material non-public information about the Company.

<div align='center'>13</div>

Corporate Governance Documents Available Online

Our corporate governance documents,
including the Audit Committee charter, Compensation Committee charter, Nominating and Corporate Governance Committee charter, and Code
of Ethics and Conduct are available free of charge on the “Investors” section of our website (www.lunaibioworks.com) under
the tab “Governance Documents”. Information contained on our website is not incorporated by reference in, or considered part
of, this proxy statement.

Director Term Limits

The Board does not currently have
a term limit policy limiting the number of years a director may serve on the Board.

Executive Officers

The names of our executive officers,
their ages, their positions with the Company, and other biographical information as of October 16, 2025, are set forth below. There are
no family relationships among our directors and executive officers. We have employment agreements with our executive officers. All of
our executive officers are at-will employees.

| Name            |     | Age |     | Position(s)                          |
| David Weinstein |     |  65 |     | Chief Executive Officer and Director |
| Nathen Fuentes  |     |  42 |     | Chief Financial Officer              |

David Weinstein

See Proposal 1: Election of Directors.

Nathen Fuentes

Mr. Fuentes most recently served
as Chief Financial Officer at Telomir Pharmaceuticals, an emerging leader in age-reversal science. Previously, Mr. Fuentes worked for
mid-market private equity sponsored companies within the specialty healthcare industry, serving as Chief Financial Officer of Emergence
Health Holdings, Divergent Dental Group, Family First Homecare and Dermatology Medical Partners. He also served as the Controller of Glytec,
as an Experienced Associate at PricewaterhouseCoopers, and held various managerial positions with homebuilding companies prior to his
experience with PricewaterhouseCoopers. Mr. Fuentes has experience leading acquisition and organic growth initiatives within highly levered
environments while managing investor relations, human resources, finance, accounting